Lille, France; Cambridge, MA; May 25, 2022 - GENFIT (NasdaqandEuronext:GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced the results of the Combined Shareholders Meeting which took place on May 25, 2022. The quorum on first convening amounted to 25.16% and shareholders approved all of the resolutions submitted by the Board of Directors.
Read more at globenewswire.comGENFIT: May 25, 2022 Combined Shareholders Meeting results
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here